)
Cingulate (CING) investor relations material
Cingulate Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Focused on developing once-daily, multi-dose therapies for ADHD and anxiety using proprietary drug delivery technology, with lead candidate CTx-1301 submitted for FDA review and a PDUFA date set for May 31, 2026.
No product revenue to date; operations funded by equity and debt, with cumulative capital raised of $116.1 million as of September 30, 2025.
Net loss for Q3 2025 was $7.3 million, up from $4.1 million in Q3 2024; accumulated deficit reached $126.1 million.
Management changes included the hiring of a new Chief Commercial Officer and interim CEO appointment following legal proceedings involving the former CEO.
Positive Phase 3 results for CTx-1301 were presented, showing dose-dependent improvements in ADHD symptoms and supporting once-daily dosing.
Financial highlights
Q3 2025 research and development expenses rose 99.5% year-over-year to $2.8 million, driven by personnel, manufacturing, and regulatory costs.
General and administrative expenses increased 69.7% year-over-year to $3.1 million, mainly due to personnel and commercial costs.
Net loss for Q3 2025 was $7.3 million, a 77.9% increase from Q3 2024; net loss for the nine months ended September 30, 2025 was $16.2 million, up 56.6% year-over-year.
Cash and cash equivalents were $6.1 million as of September 30, 2025, down $6.1 million from December 31, 2024.
Working capital was $1.6 million at quarter-end, a decrease from $7.7 million at the end of 2024.
Outlook and guidance
Cash on hand, including $6 million from a November 2025 debt issuance, is expected to fund operations into Q2 2026; an additional $7–9 million will be needed to advance commercialization through the PDUFA date.
Plans to continue seeking additional capital through equity, debt, or strategic transactions.
Focus remains on disciplined execution, operational efficiency, and long-term value creation.
Next Cingulate earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage